TQH 2929
Alternative Names: TQH-2929Latest Information Update: 09 Sep 2024
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Generalised pustular psoriasis; Psoriasis
Most Recent Events
- 19 Jun 2024 Phase-I clinical trials in Generalised pustular psoriasis in China (Parenteral) (NCT06433531)
- 03 Jun 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Psoriasis in China (Parenteral, Injection) in June 2024 (NCT06433531)
- 21 Nov 2023 Phase-I clinical trials in Psoriasis (In volunteers) in China (Parenteral) (NCT06156280)